SureNano Science (CSE: SURE) (OTCQB: SURNF) Featured in NetworkNewsAudio Editorial on Next-Generation GLP-1 Therapies

SureNano Science (CSE: SURE) (OTCQB: SURNF) Featured in NetworkNewsAudio Editorial on Next-Generation GLP-1 Therapies

Austin, Texas, May 15th, 2026, FinanceWire


This article has been disseminated on behalf of  SureNano Science Ltd.   and may include paid advertising.

SureNano Science (CSE: SURE) (OTCQB: SURNF)  was featured in a NetworkNewsAudio audio press release examining the evolution of the GLP-1 treatment market, highlighting the company’s development of GEP-44, a patented next-generation metabolic therapy designed to improve on first-generation GLP-1 drugs. The editorial noted GEP-44’s triple agonist mechanism targeting GLP-1 and peptide YY receptors, with preclinical data indicating potential benefits in appetite suppression, weight reduction and glycemic control with improved tolerability.

To view the full press release, visit  https://nnw.fm/wsiDy

About SureNano Science Ltd.

SureNano Science Ltd. is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing global health markets. SureNano Science Ltd. has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery (refer to press release dated  February 23, 2026 ). The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano(TM) surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity, and taste. The Company has an exclusive license to distribute the SureNano(TM) surfactant within Canada; Oklahoma, USA; and Colorado, USA. SureNano Science Ltd. is now developing into a pharmaceutical focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease.

NOTE TO INVESTORS: The latest news and updates relating to SURNF are available in the company’s newsroom at  https://nnw.fm/SURNF

About NetworkNewsWire

NetworkNewsWire  (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the  Dynamic Brand Portfolio @  IBN that delivers: (1) access to a vast network of wire solutions via  InvestorWire  to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and  editorial syndication to 5,000+ outlets ; (3) enhanced  press release enhancement  to ensure maximum impact; (4)  social media distribution  via IBN to millions of social media followers; and (5) a full array of tailored  corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit  https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:  https://www.NetworkNewsWire.com/Disclaimer



Contact
IBN
www.InvestorBrandNetwork.com
Editor@InvestorBrandNetwork.com